# US 9,752,189 B2 · Non-invasive early detection of solid organ transplant rejection by quantitative analysis of mixtures by deep sequencing of HLA gene amplicons using next generation systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,752,189 B2
- Document ID: US9752189B2
- Status: Granted
- Kind: B2
- Application number: 14/272,752
- Filed: 2014-05-08
- Published: 2014-11-13
- Granted: 2017-09-05
- Earliest claimed: 2013-05-08
- Assignees: Roche Molecular Systems, Inc.; The Scripps Research Institute
- Applicants: Roche Molecular Systems; The Scripps Research Institute
- Inventors: Henry Erlich; Bryan Hoglund; Cherie Holcomb; Priscilla Moonsamy; Nick Newton; Melinda Rastrou; Nancy Schoenbrunner; Alison Tsan; Daniel Salomon
- Web page: https://patentgrep.com/patent/US9752189B2

## CPC

- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- C12Q 2600/118: Prognosis of disease development
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention is a method of detecting or assessing solid organ graft (transplant) rejection by detecting donor-specific HLA alleles in a blood sample of a graft (transplant) recipient. The invention further comprises a method of detecting the presence of maternal cells in a blood sample of an offspring.

## Claims

### Claim 1

A method of generating sequence information from a solid organ graft recipient, the method comprising:
(a) providing a blood sample from the recipient;
(b) generating HLA allele sequence at the loci DPB1 Exon 2, DRB1 Exon 2, DRB3 Exon 2, DRB4 Exon 2, DRB5 Exon 2, and DOB1 Exon 2 by a method comprising:
i. contacting nucleic acid from the blood sample with a forward primer and reverse primer that have an HLA-hybridizing sequence consisting of SEQ ID NO: 1 and 7 for DPB 1 Exon 2, a forward primer and reverse primer that have an HLA-hybridizing sequence consisting of SEQ ID NO: 2 and 11 for DRB1 Exon 2, DRB3 Exon 2, DRB4 Exon2, and DRB5 Exon 2, and a forward primer and reverse primer that have an HLA-hybridizing sequence consisting of SEQ ID NO: 4 and 10 for DQB1 Exon 2, and amplifying to produce HLA amplicons;
ii. performing clonal sequencing to determine the sequence of the HLA amplicons obtained in step (i);
iii. among the sequences determined in step (ii), identifying at least one recipient HLA allele and at least one non-recipient HLA allele at the same locus.

### Claim 2 (depends on 1)

The method of claim 1, further comprising a step of quantifying the HLA alleles identified in step (iii) and calculating a ratio of the quantity of the at least one HLA allele to the sum of quantities of all HLA alleles at the same locus detected in the sample.

### Claim 3 (depends on 1)

The method of claim 1, wherein the HLA alleles identified in step (iii) include alleles for at least two loci which are in linkage disequilibrium with each other.

### Claim 4 (depends on 1)

The method of claim 1, wherein the HLA alleles identified in step (iii) include alleles for at least two loci which are not in linkage disequilibrium with each other.

### Claim 5 (depends on 1)

The method of claim 1, further comprising generating HLA allele sequence at the loci HLA-A, HLA-B, HLA-C, DQA1, and DPA1.

### Claim 6 (depends on 1)

The method of claim 1, further comprising generating HLA allele sequence at the loci DQA1, exon 2; DQB1, exon 3; and DPA1, exon 2.